(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer and dosimetry session and a presentation by Dr. Sabina Dizdarevic discussing eight-year follow-up of patient outcomes and bone ...

(UroToday.com) In EV-301, a randomized, open-label phase 3 study, enfortumab vedotin, a Nectin-4–directed therapy, significantly prolonged median overall survival by ̃3.9 months and reduced the risk ...